Background: Highly effective direct-acting antiviral (DAA) regimens (90% efficacy)are becoming
INTRODUCTION
Hepatitis C Virus (HCV) is responsible for more than 350,000 deaths every year worldwide (1). In high income countries, the main HCV transmission route is injection drug use (2) . In these countries, despite the introduction since the 80s of harm reduction measures, HCV prevalence among people who inject drugs (PWID) remains high,often above 60% (3).
Until recently,HCV treatment standard of care was a dual therapy combiningpeg-interferon and ribavirin that was moderately effective and with a high proportion of adverse events (4, 5) . New direct-acting antiviral (DAA) based interferon-freeregimens, associated with highersustained virological response (SVR) rates, better tolerance profiles, and shorter durations arenowavailable (6) (7) (8) (9) (10) (11) . These therapeutic improvements raise the question of usingHCV treatment as a mean of preventing HCV transmission in PWID, and, in the longer-term of possibly eradicating the virus.
However, the effectiveness of this strategy depends on several factors: time to diagnosis, patients' linkage to care, and treatment initiation criteriato achieve early treatment initiation; and adherence to care and treatment, to achieve a high SVR rate.
Evaluating the impact of incoming treatments or improvementsin the cascade of care on transmission inPWIDthrough traditional epidemiological studies faces issues related to feasibility and costs.
Dynamic modeling of HCV transmission inPWID is an interesting alternative allowing us to estimate the impact of various scenarioson the spread of HCV in this population. Numerous models have been proposed in the literature (12) . However, most of them did not considered the social network of PWID, which impactsviral transmission (13); and they have often estimated strategies impacting only a specific point in the cascade of care (and in particular treatment rate or treatment effectiveness), not the overall cascade.
The aim of this analysis wasto estimate, in the context of incoming DAAs regimens, the impact of HCV testing, linkage to care, and treatment efficiency improvement, andof changes in treatment initiation criteria,on HCV transmission andHCV-related morbidityinPWID. For this purpose, we useda dynamic stochastic individual-based model (IBM) with a social network model of PWID and a natural history model of chronic hepatitis C.
METHODS
Here, we present the simulated population, the structure of the model, details of the different scenarios we evaluated, and the sensitivity analyses we performed. More details regarding the hypotheses we made on parameter values are given in Supplementary Information S1.
Population
In this analysis, we focusedon a populationwith the characteristics of the PWIDpopulation in France.
We considered that the size of the population was constantat 10,000 PWID -the order of magnitude of the drug user population in the main cities of France (14) .Each PWID is characterized by 1) gender, to take into account differences of mortality between men and women (15) : the gender of each new PWIDis drawn following a probability of being a man; 2) a set of injecting partners: we draw for each PWID a group of other PWID in the population according to a random graph model (see Supplementary Information S1) susceptible ofinfecting or becoming infected by the index PWID; 3) his/her status relating to injection: current or former injector, i.e.injector after cessation of drug use; 4) his/her HCV-infection status; 5) if HCV-infected, his/her status regardingHCV infection knowledge and linkageto care, liver fibrosis stage, and treatment.
Model

Social network of injecting partners model
One of our objectives was to simulate possible pathways of HCV transmission in PWID. HCV is mainly transmitted by needles/syringes sharing in the PWID population; however paraphernalia sharing (e.g. filter, spoon) seems to play an important role too (16) . To take into account the global risk of infection for a PWID, we chose, as previously described by Rolls et al., to model the network of the sharing partners: two PWID are linked together if they inject together even without sharing needles/syringes (13) .
The mathematical literature describes numerous models of networks (17) . In the case of the injecting partners' network, the choice of a graph model is difficult, because no data are currently available on PWID social networks in France. Therefore, we used an Erdős-Rényi model where each PWID "couple" is linked with a fixed probability (18) . This model is simple to calibrate with only one parameter, which can easily be obtained with field studies: knowing , the mean number of injecting partners per PWID (i.e. the degree), and , the size of the population, the parameter of the Erdös-Rényi model is = / .
We assumed a static network, i.e. where there is no change in the links between PWID overtime. In addition, we hypothesized that each PWID who dies would be replaced by a new PWID.
Transmission and care model
We divided the population into two states: current injection injector and former injector. Each new PWID in the population is a current injector, and we attributed each one a duration for their injecting career, drawn from an exponential distribution of mean 1/ , where is the rate of drug use cessation.
Only current injectors can transmit HCV or be infected with HCV; we assume that sexual transmission of HCV in this population is negligible, as the incidence rate is approximately one per 190,000 sexual contacts for heterosexual relationships (19) . This mode of transmission was therefore not considered. (20) . After a time determined by the rate , they progress to S' (Susceptible at low risk of infection), in which their risk of infection is lower. In S (respectively S'), each PWID may be infected at rate ( ) (respectively ' ( )), with (respectively ') the infection rate per infected partner, and ( ) the PWID's number of infectious injecting partners. After infection, PWID progress to stage A (Acute hepatitis C), in which they stay for a fixed time . Acute Hepatitis C can lead to a spontaneous recovery with a probability , and the PWID returns in S'. Given the length of time between the beginning of the injecting career and the end of the acute hepatitis C, we did not consider transitions between A and S. If spontaneous recovery does not occur, PWID progress from A to UC (Undiagnosed Chronic hepatitis C) with a probability equal to 1 − . A chronic hepatitis C is diagnosed at rate , which depends on the status of current/former injectors. When a PWID is diagnosed, he/she progress to DNLC (Diagnosed and Non-Linked to care Chronic hepatitis C). A PWID is considered linked to care if he/she has one or more contact per year with a health care service regarding his/her HCV-infection. When a PWID is linked to care with a rate , he/she progress from DNLC to DLC (Diagnosed and Linked to care Chronic hepatitis C). However, he/she can be lostto-follow at rate , and in this case the PWID returns to the DLC status. We considered that PWID with cirrhosis complications (i.e. decompensated cirrhosis and/or hepatocellular carcinoma (HCC), see "Natural history" below) are always linked to care because of the severity of their illness. In each state of our model, we applied a mortality rate for deaths unrelated to HCV infection (i.e.
unrelated to a cirrhosis complication). This rate, denoted , depends on two factors: the gender of the injector and the injector's status (current or former injector) (15) . Mortality due to hepatitis C was taken into account in the natural history model described below.
Natural history model
The natural history model ( In case of successful treatment (see previous subsection), we considered that the PWID fibrosis regresses to F0, except if the patient has already developed cirrhosis (F4) (23). In this case, we considered that cirrhosis complications may still occur (23) with the same rate as that with chronic hepatitis C.
Input Parameters
Input parameters were mainly derived from ANRS-Coquelicotstudydata, which was a HCVseroprevalencecross-sectional survey conducted among drug users in France (24), and from the medical literature.Missing parameters were fitted by Approximate Bayesian Computation (ABC -see
Supplementary Information S2) (25) .
A summary of parameters and their default values are given in Supplementary Information S1, Table   S1 .
Tested scenarios
We simulated 7 scenarios, corresponding to different testing rates, linkage to care and loss to followup rates, treatment initiation criteria or SVR rates(see Table 1 ).
Scenario 1 (reference scenario) is the scenario with the parameter values presented in Table S1 in Supplementary Information, corresponding to the current cascade of care in the French PWID population.In the baseline analysis, for the nature of HCV treatment,we considered that patients receivedDAAs-based regimens. SVR for these regimens are estimated at =90% in clinical trials and treatment duration at =12 weeks (6) (7) (8) (9) (10) (11) . However, we decreased the efficacy rate of these treatments since they were derived from clinical trials in mostly non-IDUs population. To make these modifications, we applied the coefficient derived from the ratio of the SVR inreal life to the SVR in clinical trials for peg-interferon + ribavirin( =0.903) (26) . Scenario 3is the same as scenario1 with improved linkageto and retention incare: PWID are linked to care after an average duration of 0.5 years (vs. 2.6 years in scenario 1) and the loss to follow-up rate is 5%/year (vs. 13.8%/year in scenario 1).
Scenario 4isa combination of scenarios 2and3 (improved testing, linkage to and retentionin care).
Scenario 5is scenario 1 with improvedadherence to treatment.We considered that a better adherence could lead to a SVR rate similar to that of clinical trials, i.e.; =1 (vs.0.903 in scenario 1).
Scenario 6is scenario 1 with changes in treatment initiation criteria.All PWIDwho are tested, linked to care and who haveno complications of cirrhosis are treated,regardless of fibrosis stage.
Scenario 7 is the combination of scenarios 4, 5 and 6: improved testing, linkage to and retention in care; earlier treatment initiation criteria; and better adherence to treatment.
Implementation of the model and outcomes
For each scenario or sensitivity analysis, we performed 1,000 simulations. To ensure that results are comparable and to avoid the influence of the randomness in the network or population structure, we matched the simulations: each scenario was simulated on the same 1,000 simulated networks andPWID populations.
The impact of the scenarios on the prevalence andthe incidence at 10 years, and on the difference in the number of newcomplications of cirrhosis in the population after10 and 40 yearswas calculated and compared to the reference scenario. This time horizon for the number of cirrhosis complications was chosen because of the long delay before the occurrence of the complications in HCV infections.
Sensitivity analysis
We first performed a global deterministic sensitivity analysis to determine the parameters that have the most important impact under the reference scenario on the outcomes. We varied the values of the following parameters over the range of their uncertainty intervals, using data from otherhigh income countries, or using estimates from expert opinion: the infection rates ', the relative risk of infection during the first year of the injecting career, the testing rate , and the linkage to care rate and lost to follow-up rate and , the transitions rates of the natural history model, and the initial distribution in the natural history model (Supplementary Information S5, Table S3 ).
We also performed specific sensitivity analysis about the parameters where uncertainty was important.
First, when theparameter'sestimate was uncertain because of the data source: the average number of injecting partners, which was fixed at 6 by hypothesis according to limited information from other countries (see Supplementary Information S1, Table S1 ). We also varied the values of the parameter for which the situation could change -or had already changed -compared toour estimates: the infection rate ', as some evidence from different French sociological surveys show anincreaseinatrisk practices among PWID in France in recent years; and the risk of re-infection rate after a SVR, which can be higher than the primary infection rate (27, 28) . Thus, we estimated the impact of a drop to an average of 3 partners or an increase to an average of 15 partners per PWID; and the impact of increasing the reference infection rate 5 ( ′ = 0.05) and 10 times ( ′ = 0.1)on all the simulated scenarios. Figure 3 illustrates the impact of different interventions on the HCV infection prevalence and incidence at 10 years, and Figure 4 the impact on the number of complicationsof cirrhosis over 10 and 40 years. Tables S3 and S4in Supplementary Information present more details.
RESULTS
Impact of different interventions on the HCV-prevalence, incidence andrelated complications
The HCV viral prevalence was set at 42.8% at the beginning of the simulation. With scenario 1 reflecting the current situation of HCV treatment, the mean prevalence decreased to 24.9% [95% 
Impact of different strategies on the cumulative number of treatments initiated
The average cumulative number of treatment courses initiated during the first 10 years ( Figure 5 ) is higher in scenarios 6 and 7, when HCV treatment is initiated early, with 3,978 and 4,066 treatments initiated, respectively,vs. scenarios 1 to 5, when treatment is initiated at liver fibrosis stages >F2, with2,349 and 2,404treatments initiated, respectively. In addition, the distribution of the number of treatments initiated overtime is different under different scenarios. Inscenarios 3, 4, 6, and 7, more treatments were used at the beginning of the simulation period compared to scenarios 1,2, and 5.
Sensitivity analysis
The detailed results of the deterministic sensitivity analysis of the model under the reference scenario are presented in Supplementary Information S5, Figure S2 . The infection rate per partner, the transition rate between F0/F1 and F2/F3, the linkage to care/lost to follow-up rates are the parameters with the most important impact on HCV prevalence at 10 years, with variations of -3.1% to +4.7%, -2.2% to +2.6%, and -1.5% to +2.7%,respectively. The fourth parameter in order of importance is the average time to diagnosis, with variations of -0.2% to +2.5%. In the other sensitivity analyses,results were robust to variations in the average number of injecting partners(3 or 15 vs. 6, see Table S4 ). When we increased the infection rate (see Figure S3 and S4)to ′ × 5to take into account a possible increase in the PWID risk-taking behaviors,prevalence at 10 years was stable in the reference scenario, varying only from 42.8% to 43.7% [43.6%-43.8%] despite DAA use. When we increased the infection rate to ′ × 10, the prevalence at 10 years increased to 60.5% [60.4%-60.6%]. In these two cases, results were similar than in the basecase analysis.
DISCUSSION
The proposed model allows comparing different scenarios impacting every step of the cascade of care (testing, linkage to care, treatment) on both the transmission of HCV and on the HCV-related morbidity. The results of the simulations showed several important points.
First, improvinglinkage to careor increasing the SVR rate to match that achieved with new DAAsdecreased the number of cirrhosiscomplicationsby10% on average after 40 years compared to the current situation. The benefit is relatively fast when improving linkage to care (9.8% after 10 years), meanwhile increasing the SVR rate had a more long-term impact. However, changing these parameters onlyhad a small benefit on transmission,and, therefore, on the reduction in HCV prevalence(less than a 2% decrease in prevalence at 10 years). Second, the impact of improved testing was low on both transmission and morbidity. This trend is observed because,in France, HCV testing rate is already high: Francehas one of the highest rate of infection awareness in Europe (29, 30) .In the sensitivity analysis,using testing rates observed in the UK, where the time between chronic infection and diagnosis is estimated to be 7.8 years(vs. 1.25/1.45 years in our model), we obtained for example a10.4% increase of cirrhosis complications after 40 years. Thus, improved HCV testing could lead to a larger benefit in other settings.Third, initiatingHCV treatment earlier, at F0/F1 fibrosis stage, had an important impact on transmission. The impact on morbidity was relatively moderate. From an individual perspective, treating early is not associated with an important benefit because a large proportion of the infected population never develop a liver complication (31) . Those who do progress to later HCV fibrosis stages are usually detected and treated before developing complications using HCV fibrosis monitoring tools.Although, in our analysis we considered that we had perfect tools, which may be an optimistic hypothesis (32) . In contrast, from a population perspective, treating patients early does prevent HCV transmission.Finally, improvements in testing,linkage to care, and adherence to treatment in addition to early treatment initiation allowedfor a substantialdecrease inboth HCV transmission and morbidity.
The current recommendations suggest treatingpatients who reached F2,because HCV treatment regimens are costly and a high proportion of chronic hepatitis does not lead to complications (21) .
Themodel shows that if the objective of policy-makers is the eradication of the virus, treating PWID from F0, in settings where the incidence remains high, is necessary.However, even in this case, eradication will be difficult to achieve and only important improvements on the cascade of care allowed decreasing the prevalence at 10 years below 10%.
The availability of a highly effective and well-tolerated treatment could potentially cause an increase in risky practices (i.e. needle sharing or some other example), as for HIV, for which the belief about highly active antiretroviral therapy had an impact on sexual risk behaviors, even if sexual behaviors and injection practices are not easily comparable due to different social practices (33) . However, in our sensitivity analysis, we showed that our conclusions remained valid with an incidence 5 to 10 times greater than the base case.Since treatment regimens are expensive, the question of reinfection is an important one. In our model,using a re-infection rate per partner 10 times higher than the primary infection rate only had a low impact on the prevalence at 10 years, with less than 2% increase.
However, the lack of data on the PWID social network in France constrained us to use a simple model with basic properties. Particularly, it shows no community structures (i.e.strongly linked and relatively isolated groups).Further data are needed to build a more sophisticated modelandclarify this important point.
This study presents several limitations. First, we placed our model in an ideal setting where the treatment regimens are given according to the national recommendations: PWID cannot decide or be told to reject treatment for any reason. In real life,because of the assumedrisk of reinfection and poor compliance of PWID there isresistance to treatment initiation.However, with the arrival of welltolerated, injection-free treatments, with shorter durations, one may suppose that the treatment compliance will increase. Moreover, we hypothesized that there was only one line of HCV treatment and there was no retreatment after first treatment failure. We did not account for possible behavioral changes in PWID upon learning their hepatitis status (34), although they could impact the results.In this analysis, we did not limit the number of available treatment slots. Treating patients early (scenarios 6 and 7) sharply increased the cumulative amount of treatment used during the first years, which quickly reach 4,000 treatment courses after a few years, but remained stable thereafter.Given the current high costs associated with new DAAs (between 41,000 and 48,000 euros for a 12-week treatment course in France), budgetary impact will be an important issue especially when we consider treating patients early. In addition to costs, early treatment may have an important logistical and organizational impact for the medical system.
In conclusion we built an individual-based model taking into account the HCV infection, social network, natural history and cascade of care of chronic hepatitis C. We showed that to make the eradication of HCV possible, highly effective treatments are not sufficient in PWID, but an unconditional treatment, ideally associated with an improvement of access to care, is required. Several research pathways are offered by this model. In this context of costly treatment, a cost-effectiveness analysis should be considered in the future. In particular, we should evaluate the cost-effectiveness of strategies targeting PWID in the population according to their social network, that were shown to be more optimal in term of number of treatments needed (35) . In addition, harm-reduction strategies such as supervised consumption rooms, improvement of needles/syringes exchange programs or substitution therapies, represent another way to impact the HCV epidemic. HCV treatment and care is not the only efficient strategy to decrease HCV transmission and the impact of these harm-reduction strategies along with treatment should be considered in the future to eradicate HCV infection.
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